Paul Edward Kelly, Director at RELMADA THERAPEUTICS, INC. (RLMD), bought 5,000 shares at $19.20 ($96K) on 2019-10-18, disclosed to the SEC on 2019-10-21.
Open-market purchase of $96k RLMD by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade B.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $18.99 | 1,000 | $19K | 19.8% |
| 2 | $19.04 | 100 | $2K | 2.0% |
| 3 | $19.07 | 400 | $8K | 8.0% |
| 4 | $19.08 | 100 | $2K | 2.0% |
| 5 | $19.10 | 200 | $4K | 4.0% |
| 6 | $19.15 | 100 |
| $2K |
| 2.0% |
| 7 | $19.20 | 3,100 | $60K | 62.2% |
| Total | $19.14 avg | 5,000 | $96K | 100% |
| Filing → |
| RLMD | BUY | 2024-09-11 | $65K | — | Filing → |
| RLMD | SELL | 2022-04-05 | $300K | — | Filing → |
| RLMD | SELL | 2021-03-11 | $357K | — | Filing → |